Skip to main content
K

KOMIPHARM INTERNATIONAL CO., LTD. — Investor Relations & Filings

Ticker · 041960 ISIN · KR7041960006 KO Manufacturing
Open in API
Filings indexed 325 across all filing types
Latest filing 2025-04-29 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 041960

About KOMIPHARM INTERNATIONAL CO., LTD.

https://komipharm.co.kr/en/

Komipharm International Co., Ltd. is a biopharmaceutical company engaged in the development, manufacturing, and sale of products for both animal and human health. Its Animal Health Division provides a portfolio of veterinary vaccines, pharmaceuticals, and disinfectants. The company's Pharmaceutical Division is dedicated to the research and development of novel therapeutic agents, with key research areas including anticancer drugs and treatments for cancer-related pain and autoimmune diseases. Leveraging extensive experience, the company focuses on intensive R&D to expand its presence in the global bio-industry.

Recent filings

Filing Released Lang Actions
[기재정정]전환청구권행사
Share Issue/Capital Change Classification · 1% confidence The document is a regulatory filing from KOSDAQ-listed company Komipharm regarding the exercise of conversion rights for convertible bonds (CB). It details the number of shares to be issued, the adjustment of the listing date, and the remaining balance of the convertible bonds. This type of disclosure regarding capital structure changes and the issuance of new shares resulting from debt conversion falls under the 'Share Issue/Capital Change' category.
2025-04-29 Korean
전환청구권행사
Share Issue/Capital Change Classification · 1% confidence The document is a regulatory filing from Kormipharm regarding the exercise of conversion rights (전환청구권행사) for convertible bonds. It details the number of shares to be issued, the conversion price, and the impact on total outstanding shares. This type of filing relates to capital structure changes resulting from the conversion of debt into equity, which falls under the 'Share Issue/Capital Change' category.
2025-04-23 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is titled '정기주주총회결과' (Annual General Meeting Results) and provides a detailed breakdown of the voting outcomes for various agenda items, including financial statement approval, director/auditor appointments, and remuneration limits. This document is the official record of the decisions made during the shareholder meeting, which directly aligns with the definition of a Declaration of Voting Results (DVA).
2025-03-26 Korean
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Board/Management Information Classification · 1% confidence The document is a formal regulatory filing submitted to the Financial Services Commission/Korea Exchange regarding the appointment or resignation of an outside director (사외이사). This falls under the category of board and management changes, specifically the 'Board/Management Information' category.
2025-03-26 Korean
주요사항보고서(자기주식취득결정)
Transaction in Own Shares Classification · 1% confidence The document is a 'Major Matter Report' (주요사항보고서) filed with the Financial Supervisory Service and the Korea Exchange. It specifically details a 'Decision to Acquire Treasury Shares' (자기주식 취득 결정), including the number of shares, acquisition amount, purpose, and method. This falls directly under the category of a company reporting the buyback of its own shares.
2025-03-26 Korean
[기재정정]주요사항보고서(자기주식취득결정)
Transaction in Own Shares Classification · 1% confidence The document is a 'Major Matter Report' (주요사항보고서) from Komipharm regarding a decision to acquire treasury shares (자기주식 취득 결정). It details the purpose, method, and financial limits of the share buyback. According to the provided filing definitions, documents reporting a company's buyback or sale of its own shares are classified as 'Transaction in Own Shares' (POS).
2025-03-26 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.